Skip navigation



Cabume -

Cambridge Business Magazine

Innomech Develops Pilot-Scale Production System for Aston Particle Technologies

Ely-based automation consultancy GB Innomech (Innomech) has designed and developed a pilot-scale production system for Aston Particle Technologies (APT) that will help the company accelerate the commercialisation of its innovative dry particle coating technology for use within the pharmaceutical industry. More »
12 July 2017

MIND MAPS - Scanning Completed on the First Participants

Imanova is pleased to announce that the scanning has been completed on the first participants in the MIND MAPS programme. More »
11 July 2017

Owlstone Medical and Cancer Research UK (CRUK) Initiate Pan Cancer Clinical Trial to Evaluate Breath Biopsy for Early Detection

Trial aims to identify breath biomarkers to improve the early detection and diagnosis of different cancer types More »
10 July 2017

Arecor Cycle for Charity to Celebrate their 10th Year

Arecor Ltd is celebrating its 10th year and to mark the occasion we are holding a 40Km and 80Km charity cycle ride, raising funds and awareness for the JDRF organisation More »
10 July 2017

Horizon Discovery Takes Exclusive License for Novel Transposon-Based Gene Editing Technology Platform

Licensing agreements with all patent holders have been completed Enables Horizon to use gene editing directly as a therapeutic New technology has immediate applications in biomanufacturing, diagnostics, cell and gene therapy More »
05 July 2017

School for Scale-Ups Proves a Resounding Success

The first cohort of Cambridge Network's School for Scale-Ups, a programme for accelerated leadership growth, has graduated – and has given glowing feedback on the experience. More »
04 July 2017

Horizon Discovery Announces Inclusion of its Reference Standards in Successful FDA Approval

Horizon’s reference standards supported assay development and subsequent clinical trial Horizon is a leader in the application of cancer biomarkers in diagnostics and research More »
03 July 2017

CRT’s Discovery Laboratories Extends Alliance with Merck to Develop New Cancer Drugs

CANCER RESEARCH TECHNOLOGY (CRT) has signed a further deal with Merck, a leading science and technology company, to discover new cancer drugs targeting the Hippo pathway, today (Thursday). More »
29 June 2017

Abcam plc Exercises Exclusivity Provision of License and Supply Agreement with Horizon Discovery

Abcam extends a pre-existing license and supply agreement with Horizon by exercising an exclusivity provision for the period from July 2017 through June 2018 Horizon’s knockout cell models have enabled Abcam to validate its antibody catalogue at an unprecedented scale Reagent validation is an important component of efforts to improve reproducibility in medical research More »
29 June 2017

Heptares and Peptidream Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Therapeutics in Inflammatory

Heptares Therapeutics (“Heptares”), a wholly owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), and PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”; TOKYO: 4587), have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases. More »
29 June 2017

<< Previous   Page 2 of 32   Next >>